Abstract 358P
Background
Triple-negative breast cancer (TNBC) is regarded as relatively more aggressive compared to other subtypes of breast cancer with characteristic metastatic patterns and poor prognosis. The standard of care for TNBC has historically been anthracycline and taxane-based chemotherapy (ATAX). Despite its effectiveness, anthracyclines carry a small but important risk of cardiotoxicity, which is a concern in older women. The purpose of this study was to evaluate major adverse cardiovascular events in older women with TNBC.
Methods
Using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, we identified 2,215 women with TNBC diagnosed at age > 65 between 2010-2015. We compared patient and clinical characteristics according to adjuvant chemotherapy regimen (ATAX versus TAX). Logistic regression was performed to estimate the odds ratios (OR) and 95% confidence intervals (CIs), Kaplan Meier survival curves were generated to estimate three-year overall survival (OS) and cancer specific survival (CSS). Cox proportional hazards models were used to analyze OS and CSS while controlling for patient and tumor characteristics. MACE was defined as acute myocardial infarction, heart failure, potentially fatal arrhythmia, and cerebral vascular incidence. Few patients experienced a cardiac death and therefore this was excluded in the analysis.
Results
Of the 2,215 patients in our cohort, a majority of patients 1334 (60.26%) received TAX compared to ATAX 881 (39.78%). Patients who received ATAX were not more likely to experience cardiac outcomes such as acute myocardial infarction (OR 1.10, 95% CI [0.66, 1.82], p=0.724), heart failure (OR 0.73, 95% CI [0.52, 1.05], p=0.09), CVA (OR 0.76, 95% CI [0.45, 1.29], p=0.31), or potentially fatal arrhythmia (OR 0.66, 95% CI [0.29, 1.50], p=0.32) when controlling for traditional risk factors. Among patients who experienced a cardiac outcome, there was no difference in OS or CSS in patients who received TAX vs ATAX (HR 1.18, 95% CI [0.46-2.98], p=0.74 and HR 1.39, 95% CI [0.38 – 5.11] p=0.62).
Conclusions
Among older women with TNBC, receipt of adjuvant chemotherapy with ATAX was not associated with increased risk of adverse cardiac outcomes. For those who experienced a cardiac event, there was no difference in survival amongst those who received TAX compared to ATAX.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Women’s Cancer Developmental Therapeutics Program, University of Colorado Cancer Center.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
349P - The influence of diabetes on taxane-induced neurotoxicity and quality of life in breast cancer patients
Presenter: Erika Cimbro
Session: Poster session 03
350P - Quality of life data on sexual relations in early breast cancer patients
Presenter: María Garrido
Session: Poster session 03
351TiP - EORTC BCG 1984 – NOBLE: Noeoadjuvant olaparib and durvalumab for patients with BRCA-associated triple-negative breast cancer
Presenter: Emanuel Buhrer
Session: Poster session 03
352TiP - Neoadjuvant chemo-immunotherapy plus/minus fasting-like approach in stage II-III triple-negative breast cancer patients: The phase II randomized BREAKFAST-2 trial
Presenter: Claudio Vernieri
Session: Poster session 03
355P - Reduction of anthracycline use with a combined imaging and pathology prediction model in the neoadjuvant I-SPY2 trial
Presenter: Angela DeMichele
Session: Poster session 03
356P - Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study
Presenter: Soumya Gottipati
Session: Poster session 03
357P - Prediction of pathologic response to neoadjuvant chemotherapy (NAC) using diffuse optical breast scanner (DOB-Scan) in patients with locally advanced breast cancer (LABC)
Presenter: Phuong Thao Nguyen
Session: Poster session 03
359P - Unveiling the factors influencing exercise engagement in breast cancer patients: Insights from the early recovery phase
Presenter: Sujin Yeon
Session: Poster session 03